GENERAL
Natco Launches Generic Carboplatin Injection In US For Cancer Treatment
Natco Pharma Ltd has launched Carboplatin Injection, a generic version of Paraplatin, in the US market through its US subsidiary Natco Pharma USA LLC, targeting a market with estimated annual sales of $27.8 million. The Hyderabad-based pharmaceutical company has launched the product in manufacturing collaboration with Chennai-based Teyro Labs Pvt Ltd. The launch is expected […]
CW Bureau
·
Oct 19, 2026
GENERAL
Natco Pharma Pumps $14 Mn Into US’ eGenesis, Total Investment At $22 Mn
Natco Pharma is investing an additional $14 million in eGenesis Inc., a US-based biotechnology company developing genetically engineered organs for human transplantation. The investment will be made through Natco Pharma’s wholly owned subsidiaries , NATCO Pharma (Canada) Inc., which will invest $9.5 million, and NATCO Pharma South Africa Proprietary Ltd, which will invest $4.5 million. […]
CW Bureau
·
Aug 25, 2026
GENERAL
Natco Launches Generic Pomalidomide In US; Targets $3.2Bn Market
Natco Pharma, in partnership with Breckenridge Pharmaceutical, Inc., has announced the launch of Pomalidomide capsules in the United States, marking a significant expansion of its oncology and specialty portfolio in the world’s largest pharmaceutical market. The product is a generic version of Pomalyst, originally marketed by Celgene. Pomalidomide capsules are available in 1 mg, 2 […]
CW Bureau
·
Mar 3, 2026
